Sarepta Therapeutics Reports 15% Revenue Decline and $179.9 Million Net Loss in Latest Quarter

Sarepta Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded total revenues of $399.4 million, a decrease of 15% from $467.2 million in the same period last year. This decline was primarily driven by a 14% drop in product revenues, which totaled $370.0 million, compared to $429.8 million in the prior year. The company also reported a net loss of $179.9 million, a stark contrast to a net income of $33.6 million in the third quarter of 2024. The loss per share for the quarter was $(1.80), compared to earnings of $0.35 per share in the previous year.

The financial performance reflects a broader trend of increased costs and operational challenges. Total expenses surged to $502.7 million, up from $445.0 million a year earlier, largely due to a $100 million restructuring charge and a significant increase in the cost of sales, which rose by 64% to $150.8 million. Research and development expenses remained relatively stable, decreasing slightly by 2% to $218.9 million, while selling, general, and administrative expenses fell by 28% to $91.9 million, indicating cost-cutting measures in response to the company's financial situation.

Strategically, Sarepta has undergone significant changes, including a restructuring plan announced in July 2025, which involved a workforce reduction of approximately 36%, or about 500 employees. This plan aims to align the company's cost structure with its strategic priorities and enhance financial flexibility. Additionally, the company has entered into a collaboration agreement with Arrowhead Pharmaceuticals, which included a $500 million upfront payment and a $325 million investment in Arrowhead's common stock. This partnership is expected to bolster Sarepta's pipeline, particularly in the development of therapies for rare diseases.

Operationally, Sarepta's inventory levels have increased significantly, with total inventory rising to $1.3 billion as of September 30, 2025, compared to $937.9 million at the end of 2024. This increase is attributed to a buildup of inventory for its product ELEVIDYS, which has faced shipment suspensions due to safety concerns. The company has also reported a decrease in accounts receivable, reflecting lower demand for its products following the suspension of shipments to non-ambulatory patients. As of the end of the reporting period, Sarepta had $865.2 million in cash, cash equivalents, and investments, which the company believes will be sufficient to fund its operations for at least the next twelve months.

Looking ahead, Sarepta's outlook remains cautious as it navigates regulatory challenges and the impacts of its restructuring efforts. The company is in ongoing discussions with the FDA regarding the labeling and distribution of ELEVIDYS, and it is evaluating the implications of recent clinical trial results on its product pipeline. The management has indicated that while the restructuring is expected to yield long-term benefits, the immediate financial landscape is challenging, and the company may seek additional financing options to support its operational needs.